Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

Published Date: 31 Dec 2024

3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone

Read Full News

Latest News

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

(This Aug 27 story has been republished, with no changes to text.)

Alzheimer's Blood Test Gets FDA Clearance

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood ⁠test to help identify signs of Alzheimer's disease in people aged 55 and older with...

Less Seniors Taking Inappropriate Cognitive Meds

Older adults with cognitive disorders who use inappropriate medications linked to adverse cognitive effects are more likely to have poor mental health-related quality of life.

US Health Department Seeks Public Feedback on Vaccine Guidelines After Trump Order

The U.S. health department said on Friday it was seeking public feedback on federal vaccine recommendations, including how they ⁠are categorized and communicated, after...

Cognitive Therapy Boosts Brain Function in Schizophrenia

Structured cognitive remediation therapy helps boost brain activity, working memory, and quality of life and reduce severity of symptoms in patients with schizophrenia, a trial shows.

Did Breast Cancer Radiation Cause This Weird Lung Problem?

Especially peculiar since the patient had no risk factors

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

(This Aug 27 story has been republished, with no changes to text.)

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood ⁠test to help identify signs of Alzheimer's disease in people aged 55 and older with...

Older adults with cognitive disorders who use inappropriate medications linked to adverse cognitive effects are more likely to have poor mental health-related quality of life.

The U.S. health department said on Friday it was seeking public feedback on federal vaccine recommendations, including how they ⁠are categorized and communicated, after...

Structured cognitive remediation therapy helps boost brain activity, working memory, and quality of life and reduce severity of symptoms in patients with schizophrenia, a trial shows.

Especially peculiar since the patient had no risk factors

News All Time

Whole Foods Recall; RFK Jr.'s Voting Problem; Glass Particles in Biosimilar

Health news and commentary gathered by MedPage Today staff

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

News, features, and commentary about cancer-related issues

Genomic Newborn Screening Could Identify Childhood Cancer Predisposition

Testing could give doctors an early start on life-preserving cancer treatments

SBRT Misses the Mark in Prostate Cancer Trial

No improvement over intensity-modulated RT in urinary symptoms after 2 years, DFS after 3 years

What Caused This Young Man's Bladder Cancer

Occupational exposure, family history make tempting hypotheses

Dramatic Increase in Active Surveillance Use for Prostate Cancer

Soared past 90% in VA system for low-risk disease, to 61% for favorable intermediate-risk disease

Melanoma Patient on Immunotherapy Develops Severe Dermatitis

Clinicians faced with presumed dermatologic AEs urged to consider all differentials

Early Sugar Exposure and Cancer Risk; Melanoma Vaccine Win; 'Antifreeze' for CAR-T

News, features, and commentary about cancer-related issues

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

Freeman’s Lobotomy to Deep Brain Stimulation: What Changed?

The history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

Preschool-aged children exposed to screens for extended daily periods face elevated prevalence of sleep disturbances.

US Mental Health Treatment Rates Rise But Gaps Persist

Treatment rates for US adults with psychiatric disorders are modestly higher than in previous decades, but only a third receive minimally adequate care, new research shows.

Cognitive Bias Modification App Fosters Alcohol Avoidance

An Australian-designed smartphone app uses personalized cognitive bias modification to help users reduce or avoid alcohol consumption.

Schizophrenia: Nighttime Light Tied to Metabolic Dysfunction

Higher vs lower nighttime light exposure is associated with increased risk for obesity, hypertension, and dyslipidemia in patients with schizophrenia, a study suggests.

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

Consistently low PSA levels failed to signal metastasis

A Sinister Etiology for Shoulder Pain

Patient presented with what was assumed to be rotator cuff injury

Recommended News For You

Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

Novel Psychedelic Promising on Resistant Depression

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

New imaging guidelines for head and neck cancers, a step toward practice change

Recommended Articles For You

How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care? 

Hypogammaglobulinemia: A Comprehensive Guide for Patients and Caregivers 

Paving the Path to Precision: A Review of TAR-200 in the Evolving Bladder Cancer Landscape 

Neonatal Hematopoietic Transition and Blood Cell Maturation 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Independent Risk Factors for "Deaths of Despair" Found.

2.

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

3.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

4.

Infection Burden High With Myeloma T-Cell Therapies

5.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

1.

Genomic Control of Erythropoietic Stem Cell Renewal

2.

Case-Based Learning on Unexpected Cytopenia Patterns Following Advanced Therapies

3.

Subchorionic Hematoma: Causes, Symptoms, and Treatment 

4.

Clonal Hematopoiesis as a Mechanism of Age-Related Disease

5.

Transformative Insights in Oncology in Daily Practice

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Innovations in Hematology

2.

Case-Based Learning: Oncology

3.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion

4.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion

5.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot